Community seroprevalence of COVID-19 in probable and possible cases at primary health care centres in Spain.


Journal

Family practice
ISSN: 1460-2229
Titre abrégé: Fam Pract
Pays: England
ID NLM: 8500875

Informations de publication

Date de publication:
29 03 2021
Historique:
pubmed: 12 9 2020
medline: 10 4 2021
entrez: 11 9 2020
Statut: ppublish

Résumé

There is a scarcity of information about patients with mild or moderate symptoms during the coronavirus disease 2019 (COVID-19). This is especially true for those who attended and were followed up at primary care settings. We aim to measure the seroprevalence of antibodies against SARS-CoV-2 infection in a community sample of possible cases and among probable cases followed in primary care. We selected a random sample of 600 individuals stratified by age groups from a total population of 19 899 individuals from a community area in Barcelona. We also invited all the patients that had been followed by General Practitioners (GPs). For both populations, we used COVID-19 rapid lateral flow immunoassays, which qualitatively assess the presence of patient-generated Immunoglobulins G (IgG) and Immunoglobulin M (IgM). Three hundred and eleven asymptomatic individuals from the randomly selected sample participated in the study. The mean age was 43.7 years [standard deviation (SD) = 21.79] and 55% were women. Seventeen individuals were seropositive for IgM and/or IgG, resulting in an overall prevalence of 5.47% (95% confidence interval = 3.44-8.58). Six hundred and thirty-four symptomatic patients were followed up by GPs. The mean age was 46.97 years (SD = 20.05) and 57.73% were women. Of these, 244 patients (38.49%) were seropositive. Results of the multivariate logistic regression analysis showed that the odds ratio for a positive test was significantly increased in patients who had fever, ageusia and contact with a patient diagnosed with COVID-19. The seroprevalence of antibodies against SARS-CoV-2 among possible cases was lower than expected. Approximately, 40% of the symptomatic patients followed up by GPs during the peak months of the pandemic were positive.

Sections du résumé

BACKGROUND
There is a scarcity of information about patients with mild or moderate symptoms during the coronavirus disease 2019 (COVID-19). This is especially true for those who attended and were followed up at primary care settings.
OBJECTIVES
We aim to measure the seroprevalence of antibodies against SARS-CoV-2 infection in a community sample of possible cases and among probable cases followed in primary care.
METHODS
We selected a random sample of 600 individuals stratified by age groups from a total population of 19 899 individuals from a community area in Barcelona. We also invited all the patients that had been followed by General Practitioners (GPs). For both populations, we used COVID-19 rapid lateral flow immunoassays, which qualitatively assess the presence of patient-generated Immunoglobulins G (IgG) and Immunoglobulin M (IgM).
RESULTS
Three hundred and eleven asymptomatic individuals from the randomly selected sample participated in the study. The mean age was 43.7 years [standard deviation (SD) = 21.79] and 55% were women. Seventeen individuals were seropositive for IgM and/or IgG, resulting in an overall prevalence of 5.47% (95% confidence interval = 3.44-8.58). Six hundred and thirty-four symptomatic patients were followed up by GPs. The mean age was 46.97 years (SD = 20.05) and 57.73% were women. Of these, 244 patients (38.49%) were seropositive. Results of the multivariate logistic regression analysis showed that the odds ratio for a positive test was significantly increased in patients who had fever, ageusia and contact with a patient diagnosed with COVID-19.
CONCLUSIONS
The seroprevalence of antibodies against SARS-CoV-2 among possible cases was lower than expected. Approximately, 40% of the symptomatic patients followed up by GPs during the peak months of the pandemic were positive.

Identifiants

pubmed: 32914857
pii: 5904032
doi: 10.1093/fampra/cmaa096
pmc: PMC7797756
doi:

Types de publication

Journal Article Observational Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

154-159

Informations de copyright

© The Author(s) 2020. Published by Oxford University Press. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Auteurs

Patricia Montenegro (P)

Research Unit, Sardenya Primary Health Care Center (EAP Sardenya), Barcelona.
Biomedical Research Institute Sant Pau (IIB Sant Pau), Barcelona.

Carlos Brotons (C)

Research Unit, Sardenya Primary Health Care Center (EAP Sardenya), Barcelona.
Biomedical Research Institute Sant Pau (IIB Sant Pau), Barcelona.

Jordi Serrano (J)

UniversalDoctor, Barcelona, Spain.

Diana Fernández (D)

Research Unit, Sardenya Primary Health Care Center (EAP Sardenya), Barcelona.
Biomedical Research Institute Sant Pau (IIB Sant Pau), Barcelona.

Carlos Garcia-Ramos (C)

UniversalDoctor, Barcelona, Spain.

Begoña Ichazo (B)

Research Unit, Sardenya Primary Health Care Center (EAP Sardenya), Barcelona.
Biomedical Research Institute Sant Pau (IIB Sant Pau), Barcelona.

Jeannine Lemaire (J)

UniversalDoctor, Barcelona, Spain.

Irene Moral (I)

Research Unit, Sardenya Primary Health Care Center (EAP Sardenya), Barcelona.
Biomedical Research Institute Sant Pau (IIB Sant Pau), Barcelona.

Ricky Pérez Wienese (RP)

UniversalDoctor, Barcelona, Spain.

Marc Pitarch (M)

Research Unit, Sardenya Primary Health Care Center (EAP Sardenya), Barcelona.
Biomedical Research Institute Sant Pau (IIB Sant Pau), Barcelona.

Mireia Puig (M)

Research Unit, Sardenya Primary Health Care Center (EAP Sardenya), Barcelona.
Biomedical Research Institute Sant Pau (IIB Sant Pau), Barcelona.

M Teresa Vilella (MT)

Research Unit, Sardenya Primary Health Care Center (EAP Sardenya), Barcelona.
Biomedical Research Institute Sant Pau (IIB Sant Pau), Barcelona.

Jaume Sellarès (J)

Research Unit, Sardenya Primary Health Care Center (EAP Sardenya), Barcelona.
Biomedical Research Institute Sant Pau (IIB Sant Pau), Barcelona.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH